A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
- Registration Number
- NCT00931840
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Brief Summary
This is a Phase 2, multicenter, multiple-arm, open-label study to evaluate the efficacy, safety, and tolerability of EZN-2208. EZN-2208 will be administered as a single agent in patients with K-RAS mutations in the tumors. Patients with wild type K-RAS in tumors will be randomized to EZN-2208 + cetuximab or to standard of care (Camptosar® + cetuximab), patients must have failed regimens containing irinotecan (Camptosar®, CPT-11), oxaliplatin (Eloxatin®), and fluoropyrimidine.
After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival.
- Detailed Description
EZN-2208 will be administered by i.v. infusion weekly for 3 weeks in 4-week cycles. The cetuximab infusion will be administered before the EZN-2208 (Arm B) or irinotecan (Arm C) infusion. Study treatment will be continued until evidence of disease progression, unacceptable toxicity, or withdrawal of the patient's consent for participation in the study.
Approximately 220 patients will be enrolled in this study: approximately 100 patients in the K-RAS mutated arm and approximately 120 patients in the wild-type K-RAS arm.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 220
-
Patients must meet all of the following criteria to be eligible for enrollment in the study.
- Histologically confirmed CRC adenocarcinoma that is metastatic or locally recurrent CRC that is nonresectable
- Patients must agree to genetic testing of the original or metastatic CRC tumor biopsy tissue for K-RAS mutational status.
- Disease progression
- Previous therapy with irinotecan, oxaliplatin, and fluoropyrimidine either alone or in any combination(s). Patients must have radiographically documented progressive disease while receiving, or within 3 months of receiving, these agents alone or in combination.
- No more than 2 prior cytotoxic chemotherapy regimens.
- Age 18 years or older
- Measurable disease by RECIST Version 1.1
- ECOG performance status of 0 or 1
- Adequate bone marrow, renal, and hepatic function
-
Patients meeting any of the following exclusion criteria will not be eligible for enrollment.
-
Known chronic infectious disease
-
Major surgery within 3 weeks before study start
-
Known or suspected brain metastases requiring intervention with steroids and/or radiation therapy.
-
Prior chemotherapy, immunotherapy, non-investigational agent, or other therapy used to treat the cancer within 3 weeks before the scheduled administration of EZN-2208
-
History of other primary cancer within 5 years of enrollment, unless
- Curatively resected non-melanomatous skin cancer, or
- Curatively resected cervical cancer
-
Lack of recovery to Grade 1 from any reversible side effects related to the administration of an investigational agent, or other prior treatments for the cancer
-
Any condition such as uncontrollable diabetes, uncontrollable hypertension, or active infection.
-
Current participation in another clinical study with an investigational agent and/or use of an investigational drug (not including investigational use of an approved drug) in the 30 days before the first administration of EZN-2208
-
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description EZN-2208 EZN-2208, Cetuximab and Irinotecan EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days. PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL. Irinotecan + cetuximab EZN-2208, Cetuximab and Irinotecan Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks. Cetuximab + EZN-2208 EZN-2208, Cetuximab and Irinotecan Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
- Primary Outcome Measures
Name Time Method Response Rate 2011
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) 2011
Trial Locations
- Locations (60)
Location# 008
🇺🇸Columbus, Ohio, United States
Location # 079
🇨🇦Toronto, Ontario, Canada
Location # 083
🇬🇧London, England, United Kingdom
Location# 056
🇬🇧Edinburgh, Scotland, United Kingdom
Location# 066
🇮🇱Tel-Aviv, Central District, Israel
Location #033
🇺🇸Tucson, Arizona, United States
Location# 003
🇺🇸Newark, Delaware, United States
Location # 043
🇺🇸Bakersfield, California, United States
Location# 019
🇺🇸La Jolla, California, United States
Location #027
🇺🇸Stanford, California, United States
Location #050
🇺🇸Terre Haute, Indiana, United States
Location# 044
🇺🇸Fullerton, California, United States
Location# 009
🇺🇸Chicago, Illinois, United States
Location# 073
🇮🇱Jerusalem District, Israel
Location# 035
🇺🇸New York, New York, United States
Location# 024
🇺🇸Winston-Salem, North Carolina, United States
Location# 018
🇺🇸Greenville, South Carolina, United States
Location# 042
🇺🇸Alhambra, California, United States
Location# 011
🇺🇸Lubbock, Texas, United States
Location# 051
🇺🇸Northridge, California, United States
Location# 045
🇺🇸Pomona, California, United States
Location# 055
🇨🇦Rimouski, Quebec, Canada
Location# 041
🇳🇱Leiden, NL, Netherlands
Location # 049
🇺🇸Santa Barbara, California, United States
Location# 046
🇺🇸Long Beach, California, United States
Location# 022
🇺🇸Port St. Lucie, Florida, United States
Location #065
🇬🇧Dorchester, Dorset, United Kingdom
Location# 037
🇺🇸Lancaster, Pennsylvania, United States
Location# 072
🇮🇱Beer Sheva, South District, Israel
Location# 068
🇮🇱Be'er Ya'aqov, Israel
Location# 029
🇺🇸Worcester, Massachusetts, United States
Location# 002
🇺🇸New York, New York, United States
Location# 007
🇺🇸Bronx, New York, United States
Location# 069
🇮🇱Tel Hashomer, Israel
Location# 071
🇮🇱Kfar Saba, Sharon, Israel
Location# 076
🇨🇦Ottawa, Ontario, Canada
Location# 077
🇨🇦Montreal, Quebec, Canada
Location# 074
🇨🇦Montreal, Quebec, Canada
Location #061
🇬🇧London, Greater London, United Kingdom
Location# 063
🇬🇧Leeds, West Yorkshire, United Kingdom
Location # 048
🇺🇸Santa Barbara,, California, United States
Location# 052
🇺🇸Santa Maria, California, United States
Location # 030
🇺🇸Buffalo, New York, United States
Location# 067
🇮🇱Haifa, Israel
Location # 040
🇳🇱Rotterdam, The Netherlands, Netherlands
Location# 054
🇬🇧Sutton, Surrey, United Kingdom
Location# 054-2
🇬🇧London, Greater London, United Kingdom
Location# 062
🇬🇧Glasgow, Scotland, United Kingdom
Location# 047
🇺🇸Orlando, Florida, United States
Location# 020
🇺🇸Goldsboro, North Carolina, United States
Location# 004
🇺🇸Memphis, Tennessee, United States
Location# 053
🇺🇸Los Angeles, California, United States
Location #031
🇺🇸Lebanon, New Hampshire, United States
Location# 005
🇺🇸Marietta, Georgia, United States
Location #038
🇺🇸Houston, Texas, United States
Location# 057
🇬🇧London, Greater London, United Kingdom
Location# 001
🇺🇸Chapel Hill, North Carolina, United States
Location# 021
🇺🇸San Antonio, Texas, United States
Location# 070
🇮🇱Tel-Aviv, Israel
Location# 064
🇬🇧Manchester, Greater Manchester, United Kingdom